1164115-89-2
Chemical Structure
Seliforant
Synonym(s): SENS-111
- CAS No.: 1164115-89-2
- Formula:C12H21N5
- Molecular Weight:235.33
IUPAC Name: 2-isobutyl-6-(3-(methylamino)azetidin-1-yl)pyrimidin-4-amine
InChIKey: QRBVUFXEMHNIDB-UHFFFAOYSA-N
SMILES: CNC1CN(C2=NC(CC(C)C)=NC(N)=C2)C1
Biological Activity: Seliforant (SENS-111) is a selective, orally active histamine H4 receptor antagonist. Seliforant inhibits the sustained activity of vestibular neurons and modulates vestibular-related responses. Seliforant reduces spontaneous nystagmus in rats with excitotoxic acute unilateral vestibular loss. Seliforant shows no sedative effect. Seliforant can be used in research related to acute unilateral vestibular loss, vestibular dysfunction, and acute unilateral vestibular lesions[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Seliforant | 95.0% | Seliforant (SENS-111) is a selective, orally active histamine H4 receptor antagonist. Seliforant inhibits the sustained activity of vestibular neurons and modulates vestibular-related responses. Seliforant reduces spontaneous nystagmus in rats with excitotoxic acute unilateral vestibular loss. Seliforant shows no sedative effect. Seliforant can be used in research related to acute unilateral vestibular loss, vestibular dysfunction, and acute unilateral vestibular lesions. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Seliforant (Standard) | ≥98% | Seliforant (Standard) is the analytical standard of Seliforant (HY-109074). This product is intended for research and analytical applications. Seliforant (SENS-111) is a selective and orally histamine H4 receptor antagonist. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Petremann M, et al. Effect of the novel histamine H4 receptor antagonist SENS-111 on spontaneous nystagmus in a rat model of acute unilateral vestibular loss. Br J Pharmacol. 2020;177(3):623-633. [Content Brief]
- [2]. Venail F, et al. Safety, tolerability, pharmacokinetics and pharmacokinetic-pharmacodynamic modelling of the novel H4 receptor inhibitor SENS-111 using a modified caloric test in healthy subjects. Br J Clin Pharmacol. 2018;84(12):2836-2848. [Content Brief]
Keywords
